

## NeurAxon Appoints Robert Medve, M.D., as Chief Medical and Regulatory Officer

WALTHAM, MA. August 7, 2007 – [NeurAxon Inc.](#), a developer of next generation pain therapeutics targeting neuronal [nitric oxide synthase](#) (nNOS), announced today the appointment of Robert Medve, M.D., to the newly created position of Chief Medical and Regulatory Officer of the Company. Dr. Medve was most recently Vice President of Science, Research and Development of Lifetree Clinical Research, a clinical research organization focused on clinical trials for pain indications.

“We believe that Robert’s experience in successfully transitioning therapeutic candidates from research to clinical trials and the strategic management of clinical development programs for pain indications is an ideal fit for NeurAxon,” stated Lawrence Bloch, M.D., J.D., Chief Executive Officer of NeurAxon. “Robert has been instrumental in the clinical development and approval of several products, including Topamax<sup>®</sup> for migraine prevention and analgesics including Vicoprofen<sup>®</sup>, Ultracet<sup>®</sup>, Zaldiar<sup>®</sup> and Duragesic<sup>®</sup> (pediatric). We look forward to Robert applying his broad expertise to our promising pipeline of next generation pain therapeutics as we plan additional clinical trials for our lead program, NXN-188 for migraine, and as we bring additional product candidates from the NeurAxon portfolio into the clinic.”

“As a physician and a migraineur myself, I appreciate that there are significant unmet medical needs in the treatment of migraine as well as other pain indications, and I believe that NeurAxon’s approach through the inhibition of neuronal nitric oxide synthase has great promise,” commented Robert Medve, M.D. “For example, the dual mechanism of action of NeurAxon’s lead candidate, NXN-188, through nNOS inhibition and 5HT agonism has the potential to provide substantial improvements over the current standards of care for the treatment of acute migraine. I am enthusiastic about being part of the NeurAxon leadership team and contributing to the development of these exciting drug candidates.”

In addition to Lifetree Clinical Research, Dr. Medve has held senior positions in pharmaceutical and biotechnology companies including Metaphore Pharmaceuticals, Johnson & Johnson and Knoll Pharmaceutical Company. He has extensive experience in managing pre-clinical and clinical drug development programs and has leadership experience in all aspects of regulatory interaction in the US and Europe. Dr. Medve earned his doctorate of medicine at Jefferson Medical College in Philadelphia, Pennsylvania, and he completed his residency in the anesthesia department at Thomas Jefferson University Hospital. Dr. Medve completed a pain management fellowship at Roswell Park Cancer Institute and the Children’s Hospital of Buffalo, where Dr. Medve also served as the Director of Pediatric Pain Management.

Topamax<sup>®</sup> and Ultracet<sup>®</sup> are registered trademarks of Ortho-McNeil Neurologics, a division of Johnson & Johnson.

Vicoprofen<sup>®</sup> is a registered trademark of Knoll Pharmaceutical Company, an Abbott Laboratories Company.

Zaldiar<sup>®</sup> is a registered trademark of Grunenthal.

Duragesic<sup>®</sup> is a registered trademark of Janssen, a Johnson & Johnson Company.

**About NeurAxon Inc.**

NeurAxon Inc. ([www.nrxn.com](http://www.nrxn.com)) is a leader in discovering and developing next generation pain therapeutics targeting neuronal nitric oxide synthase (nNOS), an enzyme involved in modulating pain and central nervous system neuronal sensitization.

**Contact:**

Chris Erdman  
MacDougall Biomedical Communications  
508.647.0209 x14